NZ744390A - Protease-activated t cell bispecific molecules - Google Patents
Protease-activated t cell bispecific moleculesInfo
- Publication number
- NZ744390A NZ744390A NZ744390A NZ74439017A NZ744390A NZ 744390 A NZ744390 A NZ 744390A NZ 744390 A NZ744390 A NZ 744390A NZ 74439017 A NZ74439017 A NZ 74439017A NZ 744390 A NZ744390 A NZ 744390A
- Authority
- NZ
- New Zealand
- Prior art keywords
- protease
- seq
- amino acid
- activatable
- cdr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides acting as masking moieties. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
Claims (29)
1. A protease-activatable T cell activating bispecific molecule comprising (a) a first antigen binding moiety capable of specific binding to CD3, wherein the first antigen binding moiety is an antibody or nt f; 5 (b) a second antigen binding moiety capable of specific binding to a target cell n, wherein the second antigen binding moiety is an antibody or fragment thereof; and (c) a masking moiety covalently attached to the protease-activatable T cell activating bispecific molecule through a se-cleavable linker, wherein the g moiety is capable of ic g to the idiotype of the first or the second 10 antigen binding moiety thereby ibly concealing the first or the second antigen binding moiety, wherein the masking moiety is an anti-idiotypic scFv.
2. The protease-activatable T cell activating bispecific molecule of claim 1, wherein the masking moiety is covalently attached to the first n binding moiety and reversibly conceals the first antigen binding moiety. 15
3. The protease-activatable T cell activating bispecific molecule of claim 1 or 2, wherein the masking moiety is covalently attached to the heavy chain variable region of the first antigen binding moiety.
4. The protease-activatable T cell activating bispecific molecule of any one of claims 1 to 3, wherein the second n binding moiety is capable of specific binding to a target cell 20 antigen selected from the group consisting of FolR1, HER1, HER2 and elin.
5. The protease-activatable T cell activating bispecific molecule of any one of claims 1 to 4, wherein the first and the second antigen binding moiety are fused to each other, optionally via a peptide linker.
6. The protease-activatable T cell activating ific molecule of any one of claims 1 to 5, 25 additionally comprising an Fc domain composed of a first and a second subunit capable of stable association.
7. The protease-activatable T cell activating bispecific molecule of claim 6, wherein the Fc domain is an IgG, specifically an IgG1 or IgG4, Fc domain.
8. The protease-activatable T cell activating bispecific molecule of any one of claims 6 or 7, 30 wherein the Fc domain exhibits reduced binding affinity to an Fc or and/or reduced effector function, as ed to a native IgG1 Fc domain.
9. The protease-activatable T cell activating bispecific molecule of any one of claims 1 to 8, wherein the masking moiety comprises a heavy chain variable region comprising: (a) a heavy chain complementarity determining region (CDR H) 1 amino acid sequence of SYGVS (SEQ ID NO:26); (b) a CDR H2 amino acid sequence of IIWGDGSTNYHSALIS (SEQ ID NO:27); (c) a CDR H3 amino acid sequence of GITTVVDDYYAMDY (SEQ ID NO:28); and a 5 light chain variable region comprising: (d) a light chain (CDR L)1 amino acid sequence of RASENIDSYLA (SEQ ID ; (e) a CDR L2 amino acid sequence of AATFLAD (SEQ ID NO:30); and (f) a CDR L3 amino acid sequence of QHYYSTPYT (SEQ ID NO:31).
10. The se-activatable T cell activating bispecific molecule of any one of claims 1 to 9, 10 wherein the protease cleavable linker comprises at least one protease recognition sequence.
11. The protease-activatable T cell activating ific molecule of claim 10, wherein the protease cleavable linker comprises the protease recognition ce RQARVVNG (SEQ ID NO:36). 15
12. The protease-activatable T cell activating bispecific molecule of any one of claims 1 to 11, n the first antigen binding moiety is capable of specific binding to CD3 and comprises a heavy chain le region comprising: a) a heavy chain complementarity determining region (CDR H) 1 amino acid sequence of TYAMN (SEQ ID NO:44); 20 b) a CDR H2 amino acid sequence of RIRSKYNNYATYYADSVKG (SEQ ID NO:45); and c) a CDR H3 amino acid sequence of SYVSWFAY (SEQ ID NO:46); and a light chain variable region comprising: d) a light chain (CDR L)1 amino acid sequence of VTTSNYAN (SEQ ID 25 NO:17); e) a CDR L2 amino acid sequence of GTNKRAP (SEQ ID NO:18); and f) a CDR L3 amino acid sequence of ALWYSNLWV (SEQ ID NO:19).
13. The protease-activatable T cell activating bispecific molecule of any one of claims 1 to 12, wherein the first antigen binding moiety is capable of specific binding to CD3 and 30 comprises a heavy chain le region comprising the amino acid sequence of SEQ ID NO: 43 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 55.
14. The protease-activatable T cell activating ific molecule of any one of claims 1 to 13, wherein the second antigen binding moiety is capable of specific binding to FolR1 and comprises a heavy chain variable region comprising: a) a heavy chain complementarity determining region (CDR H) 1 amino acid 5 sequence of NAWMS (SEQ ID ; b) a CDR H2 amino acid sequence of RIKSKTDGGTTDYAAPVKG (SEQ ID NO:15); and c) a CDR H3 amino acid sequence of PWEWSWYDY (SEQ ID NO:16); and a light chain variable region sing: 10 d) a light chain (CDR L)1 amino acid sequence of GSSTGAVTTSNYAN (SEQ ID NO:17); e) a CDR L2 amino acid sequence of GTNKRAP (SEQ ID ; and f) a CDR L3 amino acid sequence of ALWYSNLWV (SEQ ID NO:19).
15. An idiotype-specific polypeptide for reversibly concealing an anti-CD3 n binding 15 site of a molecule, wherein the idiotype-specific polypeptide is an anti-idiotype scFv wherein the idiotype-specific polypeptide is covalently attached to the molecule through a linker.
16. The idiotype-specific polypeptide of claim 15, wherein the linker is a peptide .
17. The idiotype-specific polypeptide of claim 15 or 16, wherein the linker is a protease- 20 cleavable .
18. The idiotype-specific polypeptide of any one of claims 15 to 17, wherein the peptide linker comprises at least one protease recognition site.
19. The idiotype-specific polypeptide of claim 18, wherein the protease cleavable linker comprises the protease recognition sequence RQARVVNG (SEQ ID NO:36). 25
20. The idiotype-specific polypeptide of any one of claims 18 or 19, wherein the molecule is a T-cell activating bispecific molecule.
21. The idiotype-specific polypeptide of any one of claims 15 to 20, comprising a heavy chain variable region comprising: (a) a heavy chain complementarity ining region (CDR H) 1 amino acid 30 sequence of SYGVS (SEQ ID NO:26); (b) a CDR H2 amino acid sequence of IIWGDGSTNYHSALIS (SEQ ID NO:27); (c) a CDR H3 amino acid sequence of GITTVVDDYYAMDY (SEQ ID ; and a light chain variable region comprising: (d) a light chain (CDR L)1 amino acid sequence of RASENIDSYLA (SEQ ID NO:29); (e) a CDR L2 amino acid sequence of AATFLAD (SEQ ID NO:30); and (f) a CDR L3 amino acid sequence of QHYYSTPYT (SEQ ID NO:31).
22. A pharmaceutical composition comprising the protease-activatable T cell activating 5 bispecific molecule of any one of claims 1 to 14 or the idiotype-specific polypeptide of any one of claims 15 to 21 and a ceutically acceptable carrier.
23. A protease-activatable T cell activating bispecific molecule of any one of claims 1 to 14, the idiotype-specific polypeptide of any one of claims 15 to 21 or the pharmaceutical composition of claim 22 for use as a medicament, wherein the medicament is for treating 10 or ng progression of cancer, treating or ng progression of an immune related disease, or enhancing or ating an immune response or function.
24. An isolated polynucleotide ng the protease-activatable T cell activating bispecific antigen binding molecule of any one of claims 1 to 14 or the idiotype-specific ptide of any one of claims 15 to 21. 15
25. A vector, particularly an expression vector, comprising the polynucleotide of claim 24.
26. A host cell comprising the cleotide of claim 24 or the vector of claim 25, with the proviso that said host cell is not present in a human being.
27. A method of ing a se-activatable T cell activating bispecific molecule or an idiotype-specific polypeptide, comprising the steps of a) culturing the host cell of claim 20 26 under ions suitable for the expression of the protease-activatable T cell activating bispecific molecule or the idiotype-specific polypeptide and b) recovering the protease-activatable T cell activating bispecific molecule or the idiotype-specific ptide.
28. Use of the protease-activatable T cell ting bispecific molecule of any one of claims 25 1 to 14 or the idiotype-specific polypeptide of any one of claims 15 to 21 for the manufacture of a medicament for treating or delaying progression of cancer, treating or delaying progression of an immune related disease, or enhancing or stimulating an immune response or function.
29. A method of treating or ng progression of cancer, treating or delaying progression 30 of an immune related disease, or enhancing or stimulating an immune response or function in a non-human animal, comprising administering to said non-human animal a therapeutically effective amount of a composition comprising the protease-activatable T cell activating bispecific molecule of any one of claims 1 to 14. PC'17EP20 l
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16161740 | 2016-03-22 | ||
| US201662433327P | 2016-12-13 | 2016-12-13 | |
| PCT/EP2017/056556 WO2017162587A1 (en) | 2016-03-22 | 2017-03-20 | Protease-activated t cell bispecific molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ744390A true NZ744390A (en) | 2025-02-28 |
| NZ744390B2 NZ744390B2 (en) | 2025-06-04 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| US20220275087A1 (en) | 2022-09-01 |
| US20190119383A1 (en) | 2019-04-25 |
| MY198233A (en) | 2023-08-15 |
| US11242390B2 (en) | 2022-02-08 |
| PH12018502035A1 (en) | 2019-07-08 |
| IL260637B2 (en) | 2023-08-01 |
| MX2018011542A (en) | 2019-02-07 |
| RS64266B1 (en) | 2023-07-31 |
| DK3433280T3 (en) | 2023-06-19 |
| RU2018136567A3 (en) | 2021-02-19 |
| RU2018136567A (en) | 2020-04-22 |
| LT3433280T (en) | 2023-07-10 |
| JP2019514850A (en) | 2019-06-06 |
| IL260637B1 (en) | 2023-04-01 |
| CL2018002507A1 (en) | 2018-12-21 |
| ZA201804973B (en) | 2023-02-22 |
| US20230119537A1 (en) | 2023-04-20 |
| IL260637A (en) | 2018-09-20 |
| PE20231511A1 (en) | 2023-09-26 |
| US20260055184A1 (en) | 2026-02-26 |
| SI3433280T1 (en) | 2023-07-31 |
| HUE061946T2 (en) | 2023-09-28 |
| HRP20230528T1 (en) | 2023-08-04 |
| JP7015244B2 (en) | 2022-02-02 |
| UA127308C2 (en) | 2023-07-19 |
| FI3433280T3 (en) | 2023-06-06 |
| PL3433280T3 (en) | 2023-07-31 |
| ES2947230T3 (en) | 2023-08-03 |
| DK3433280T5 (en) | 2024-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112851808B (en) | IGF-1R antibody and its use as a targeting carrier for treating cancer | |
| HRP20230528T1 (en) | Protease-activated t cell bispecific molecules | |
| KR102033805B1 (en) | Antigen binding protein and its use as addressing product for the treatment of cancer | |
| US20170210818A1 (en) | Constant region antibody fusion proteins and compositions thereof | |
| CA2890265C (en) | Antigen binding proteins and their use as addressing product for the treatment of cancer | |
| CN109563169A (en) | Anti-HLA-G specific antibody | |
| CA3114467C (en) | Anti pd-l1 antibody and use thereof | |
| US20240218065A1 (en) | Multispecific antigen-binding protein and use thereof | |
| CN105008398A (en) | Anti-HER2 antibodies and conjugates thereof | |
| RU2013125459A (en) | ANTIBODIES AGAINST c-Met RECEPTOR PROTEIN | |
| CN110914297A (en) | Anti-human interleukin 2 antibody and use thereof | |
| JP2021512151A5 (en) | ||
| CN111378044A (en) | Antibody fusion protein, preparation method and application thereof | |
| KR102281405B1 (en) | Anti- VISTA antibody and Use Thereof | |
| TW202334204A (en) | Conditionally activated antigen binding polypeptide complexes and methods of use thereof | |
| US20240327543A1 (en) | Multispecific antigen-binding protein and use thereof | |
| Akbari et al. | Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR) | |
| WO2025021118A1 (en) | Ligand-drug conjugate and linker for conjugation | |
| CN113061177B (en) | CD73 enzyme activity related antigen epitope and preparation method of specific antibody aiming at epitope | |
| CN101864398B (en) | Monoclonal antibody of anti-gonadotropin-releasing hormone receptor and application thereof | |
| NZ744390B2 (en) | Protease-activated t cell bispecific molecules | |
| WO2023134716A1 (en) | Bispecific antibody binding to b7h3 and nkp30, and application thereof | |
| TH1801005757A (en) | T cell bispecific molecule that is activated by protease. | |
| NZ794344A (en) | Tgfβr2 extracellular domain truncated molecule, fusion protein of tgfβr2 extracellular domain truncated molecule and anti-egfr antibody, and anti-tumor use of fusion protein | |
| RU2021112298A (en) | NEW PROTEIN COMPOSITIONS OBTAINED BY RATIONAL DESIGN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |